BiotechTube
Home/Pipeline/Anti-CD33/Anti-CLL1 cCAR

Anti-CD33/Anti-CLL1 cCAR

Acute Myeloid Leukemia (AML)

Clinical TrialActive

Key Facts

Indication
Acute Myeloid Leukemia (AML)
Phase
Clinical Trial
Status
Active
Company
iCell Gene Therapeutics

About iCell Gene Therapeutics

iCell Gene Therapeutics is a pioneering clinical-stage biotech developing novel CAR-engineered cell therapies for autoimmune diseases and cancer. The company claims a first-in-world clinical application of CAR therapy for lupus, with data showing durable remission approaching six years, and is also advancing programs for T-cell malignancies and acute myeloid leukemia (AML). Its strategy leverages a proprietary technology platform, including compound CARs (cCARs) and non-gene editing approaches, supported by in-house viral vector and GMP manufacturing capabilities in China to enable cost-effective production.

View full company profile

Therapeutic Areas

Autoimmune DiseasesOncology

Other Acute Myeloid Leukemia (AML) Drugs

DrugCompanyPhase
Mipletamig (APVO436)Aptevo TherapeuticsPhase 1/2
lomonitinibLomond TherapeuticsIND-Enabling
lonitoclaxLomond TherapeuticsPhase 1
Menin InhibitorLomond TherapeuticsDiscovery
AB8939AB SciencePhase 1
Small-Molecule TherapeuticAIkido LabsPre-clinical
ADI-PEG 20 (pegargiminase)Polaris PharmaPhase 1
NC525NextCurePreclinical
ACD-101Advanced Cellular DynamicsPhase 1
ABD-3001Advanced BiodesignPhase 1
HC-7366HiberCellPhase 1b
Prexigebersen (BP1001)Bio-Path HoldingsPhase 2